Source comparison
BPC-157 Research Hepatic Considerations — Comparison Across Peptide Classes
BPC-157 Peptidase cleavage in peripheral tissues; minimal hepatic metabolism None documented in published studies; no case reports of hepatic enzyme elevation Baseline + serial monitoring recommended for co-administration protocols Yes. Multiple studies show r
This comparison does not assign a generated winner or score.
- BPC-157
- Peptidase cleavage in peripheral tissues; minimal hepatic metabolism
- None documented in published studies; no case reports of hepatic enzyme elevation
- Baseline + serial monitoring recommended for co-administration protocols
- Yes. Multiple studies show reduced ALT/AST in chemically induced liver injury models
- Low hepatic risk profile; suitable for protocols requiring hepatic endpoint monitoring. Lack of human PK data is the primary limitation.
- TB-500 (Thymosin Beta-4)
- Hepatic and renal clearance; some cytochrome P450 involvement
- Low; isolated case reports of transient AST elevation at high doses
- Baseline + monthly monitoring if used >8 weeks or at doses >5mg/week
- Limited evidence; one study suggested improved fibrosis markers in hepatic injury models
- Moderate hepatic burden at standard doses. Co-administration with hepatotoxic compounds requires caution.
- Melanotan II
- Hepatic metabolism via peptidase and potential CYP involvement
- Moderate; anecdotal reports of elevated liver enzymes at doses >1mg/day
- Baseline + biweekly monitoring for first month, then monthly
- None documented
- Higher hepatic monitoring requirement due to dose-dependent enzyme elevation risk. Not suitable for hepatic endpoint studies.
- GHK-Cu (Copper Peptide)
- Renal excretion; copper component metabolized hepatically
- Low for peptide; moderate concern due to copper accumulation in liver with chronic use
- Baseline + monthly monitoring; serum copper and ceruloplasmin if used >12 weeks
- Yes. Copper is a cofactor in hepatic antioxidant systems, but excess copper is hepatotoxic
- Biphasic risk profile: protective at physiologic copper levels, toxic at supraphysiologic. Requires copper status monitoring.
- Sermorelin
- Hepatic and renal clearance; metabolized to inactive fragments
- Low; no documented hepatotoxicity in clinical trials
- Baseline recommended; serial monitoring not typically required unless co-administered with hepatic stressors
- Low hepatic burden; suitable for long-term protocols. Well-characterized PK profile reduces uncertainty.
- BPC-157 stands out for its apparent lack of hepatic enzyme elevation across animal models. A finding that positions it uniquely among investigational peptides. The absence of human pharmacokinetic trials is the constraint that prevents definitive safety claims, but the preclinical safety profile is remarkably consistent.